Fosun Pharma Invests RMB 414 Million in Xingyao Kunze to Advance Global Clinical Development of Functional Cure for Hepatitis B
Fosun Pharmaceutical
Healthcare Industry Group
Hepa Thera
Innovative Drug Developer in the Field of Hepatology
(Shanghai, China, May 28, 2026) Recently, Fosun Pharmaceutical (600196.SH; 02196.HK) announced that it will invest a total of approximately RMB 414 million through its controlling subsidiary, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., to participate in the Series B financing and equity transfer transaction of Suzhou Hepa Thera Biotech Co., Ltd. (hereinafter referred to as "Hepa Thera"). The total amount of this financing round and equity transfer exceeds RMB 630 million. Upon completion of all transactions, Fosun Pharmaceutical is expected to hold approximately a 20.87% equity stake in Hepa Thera, further deepening its strategic layout in the liver disease treatment sector.
Hepa Thera is a product platform company focused on the development of innovative therapies for liver diseases, incubated and majority-controlled by the Fosun Health Capital New Drug Fund, which was co-established by Fosun Pharmaceutical. Its core pipeline, a combination regimen of HT-101 (siRNA) and HT-102 (neutralizing antibody), aims to achieve a functional cure for chronic hepatitis B (CHB) through an innovative combination therapeutic strategy. This combination therapy has been granted Breakthrough Therapy Designation by China's National Medical Products Administration (NMPA). Interim results previously disclosed at the 2025 AASLD Annual Meeting demonstrated that the HT-101 + HT-102 combination achieved rapid clearance and a clearance rate of up to 90% in CHB patients, highlighting its clinical potential as a next-generation functional cure regimen for hepatitis B and preliminarily validating the differentiated value of the dual-mechanism "siRNA + neutralizing antibody" combination strategy. During the European Association for the Study of the Liver (EASL) Congress held from May 27 to 30, 2026, the latest Phase II clinical data for the HT-101 + HT-102 combination regimen was selected for presentation as a "Best Breakthrough Abstract Poster," further earning authoritative international recognition.
Chen Yuqing
Chairman of Fosun Pharmaceutical
The functional cure of hepatitis B is a long-awaited hope for patients worldwide. Hepa Thera's combination regimen of HT-101 and HT-102 has already demonstrated breakthrough potential in clinical trials. Fosun Pharmaceutical has long been deeply engaged in the field of liver diseases, and we remain steadfastly committed to providing patients with superior treatment options. This investment not only represents a significant expansion of Fosun Pharmaceutical's pipeline in liver disease therapeutics, but also stands as a firm commitment to supporting original innovation in China and helping domestic innovative drugs reach the global market. We will fully leverage our strengths in clinical research, manufacturing, and global commercialization networks, partnering with stakeholders to accelerate the delivery of this breakthrough therapy to patients worldwide.
The proceeds from this financing round are expected to be primarily allocated to the global clinical development and regulatory submissions for Hepa Thera's core products, the in-depth expansion of combination therapy strategies, the systematic development of commercialization and industrialization capabilities, and the comprehensive enhancement of capital market planning and organizational capabilities.
This round of financing was jointly completed by Shanghai Fosun Pharmaceutical Industry Development Co., Ltd., Hangzhou Cathay Capital, Zhuhai Huajin Investment, TG Sino-Dragon Fund II L.P., Qianhe Capital, Deshi Capital, Taihao Venture Capital, and other institutions and individuals.
As an early incubator and ongoing supporter of Hepa Thera, Fosun Pharmaceutical has further strengthened its multi-dimensional synergies with Hepa Thera across R&D, clinical development, commercial manufacturing, and global commercialization through this strategic capital injection. Moving forward, Fosun Pharmaceutical will collaborate with new and existing shareholders to jointly accelerate clinical breakthroughs and the global market launch of functional cure therapies for hepatitis B, delivering more breakthrough treatment options to hepatitis B patients worldwide.
Contact Information
Media:pr@fosunpharma.com
Investor:ir@fosunpharma.com
